Heterocyclic Compounds

Matches 351 - 400 out of 30,869	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/150523A1	PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
WO/2023/150535A1	PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
WO/2023/150526A1	COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 Arylsulfonamides of 5-substituted octahydrocyclopenta[c]pyrroles, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatr...
WO/2023/148501A1	HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
WO/2023/150525A1	COMPETITIVE AND NONCOMPETITIVE PIPERIDINE SULFONYL INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 Arylsulfonamides of 4-substituted-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such a...
WO/2023/150150A1	PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
WO/2023/148544A1	CRYSTALLINE FORM OF ISAVUCONAZONIUM SULFATE AND A PROCESS FOR ITS PREPARATION The present invention relates to a crystalline form of isavuconazonium sulfate. The present invention also relates to a process for preparation of isavuconazonium sulfate and a pharmaceutical composition containing the crystalline isavuc...
WO/2023/143249A1	PROTEIN DEGRADATION COMPOUND TARGETING MALT1 Disclosed in the present invention are a compound that inhibits MALT1 and promotes the degradation of MALT1 by means of recruiting E3 ubiquitin ligase, and the use of the compound in the preparation of a drug for treating related disease...
WO/2023/144764A1	BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS The present invention relates to substituted heterocyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes the me...
WO/2023/069514A9	BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY This disclosure relates to compounds of formulae I, II and III useful for degrading ITK via a ubiquitin proteolytic pathway. This disclosure also provides pharmaceutically acceptable compositions comprising said compounds, and methods of...
WO/2023/142214A1	3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE A series of 3-hydroxy-5-(isoxazol-5-yl) pyridine formylglycine compounds, a preparation method, a pharmaceutical composition, and the use. A structure of the compounds is shown as formula (I), and the compound derivatives comprise pharma...
WO/2023/143605A1	PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS The invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially KRAS G12C inhibitors.The present invention provides a direct enantioselective ch...
WO/2023/146785A1	PYRROLIDINE COMPOUNDS The present disclosure provides compounds of the formula (III) and their pharmaceutically acceptable salts, and compounds of the formula (IV) and their pharmaceutically acceptable salts, and pharmaceutical compositions comprising these c...
WO/2023/146989A1	COMPOUNDS AND METHODS OF USE Provided are compounds of Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined h...
WO/2023/144450A1	COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS According to an aspect of the present invention, there is provided a [1,2,4]triazolo[3,4-b]benzothiazole scaffold, which can be used to inhibit efficiently human PARP enzymes. The compounds disclosed bind to the nicotinamide pocket of th...
WO/2023/144793A1	POL THETA INHIBITORS The present invention relates to compounds of formula (I), that possess DNA polymerase theta (POLQ) enzyme inhibitory activity, methods for their preparation, pharmaceutical compositions containing them, and their use in the treatment or...
WO/2023/146897A1	2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular dis...
WO/2023/144559A1	ANTAGONIST OF ADENOSINE RECEPTORS The present invention relates to compounds of formula I shown below: wherein R1, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...
WO/2023/146511A1	COMPOUNDS AND METHODS OF USE THEREOF Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
WO/2023/141852A1	CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
WO/2023/146991A1	COMPOUNDS AND METHODS OF USE Provided are compounds of Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ring A, Ring B, X, R1, R2 and n are as defined he...
WO/2023/147531A1	INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosph...
WO/2023/143603A1	ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES Use of a compound of Formula I for treating atherosclerosis and related diseases, disorders and conditions in a subject in need of such treatment, wherein the subject in need of such treatment is a subject carrying one or more genetic mu...
WO/2023/139085A1	NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
WO/2023/141300A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
WO/2023/139402A1	INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed. Formula (C)
WO/2023/139132A1	FUNCTIONALIZED AMINOTHIAZOLES The present invention relates to novel antagonists of the A2B adenosine receptor and pharmaceutical compositions comprising said antagonists as well as their uses for the treatment and prevention of disorders known to be susceptible to i...
WO/2023/141225A1	FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazo...
WO/2023/138412A1	FUSED PYRIMIDIN-2-AMINE COMPOUNDS AS CDK20 INHIBITORS The present disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvate, stereoisomer, or isotopic variant thereof useful as CDK20 inhibitors, pharmaceutical compositions comprising the same, and use ther...
WO/2023/140649A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound represented by chemical formula 1 and to an organic light-emitting device comprising: a first electrode; a second electrode; and one or more organic material layers provided between the fir...
WO/2023/134739A1	SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF Provided in the present disclosure are a six-membered cyclothiazole compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof in the prevention...
WO/2023/136295A1	PYRIMIDINE COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT One purpose of the present invention is to provide a compound which is suitable for use as a material for a capping layer in an organic EL element, has a high refractive index in a wavelength range from 450 nm to 750 nm, and has a low ex...
WO/2023/136457A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention relates to a novel compound and an organic light-emitting device comprising same.
WO/2023/137030A1	MODULATORS OF TREX1 Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.
WO/2023/134765A1	FIVE-MEMBERED-RING-CONTAINING DERIVATIVES, PREPARATION METHOD THEREFOR, AND USES THEREOF The present invention relates to five-membered-ring-containing derivatives, a preparation method therefor, and the uses thereof. In particular, the present invention relates to compounds represented by a general formula, a preparation me...
WO/2023/134656A1	PEPTIDYL NITRILE COMPOUND AND USE THEREOF Provided are a peptidyl nitrile compound and a use thereof; specifically provided are a compound represented by formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
WO/2023/137034A1	COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
WO/2023/134608A1	FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS Provided is a class of fused ring compounds that serve as HPK1 inhibitors. Specifically, provided are a compound represented by general formula (1), a preparation method therefor, and a use of the compound of general formula (1) and isom...
WO/2023/135330A1	DEOXYCYTIDINE KINASE INHIBITORS The present invention relates to compounds of formula (I) as deoxycytidine kinase inhibitors and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use f...
WO/2023/136586A1	COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
WO/2023/018472A9	AMINOARYL-INTEGRIN AGONISTS COMPOUNDS N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
WO/2023/132369A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these.　Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
WO/2023/133217A1	2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
WO/2023/131868A1	HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of GLUT9 for the treatment or prevention of hyperuricemia and gout.
WO/2023/131649A1	BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS The present invention relates to new norbornen analogues of formula (I), wherein the norbornen moiety is in R5 and to the use of norbornen analogues as a drug, in particular for the prevention and/or treatment of a mycobacterial infectio...
WO/2023/133181A1	KRAS INHIBITORS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2023/133183A1	KRAS INHIBITORS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2023/131690A1	SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS The invention relates to substituted heterocycles of the general formula (I), wherein W is thiazole, thiophene, pyrazole, imidazole or isoxazole, and the use of the compounds of the present invention for the treatment and/or prevention o...
WO/2023/131976A1	IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIM IDAZOLE-6-CARBOXAMIDE The present invention relates to an improved process for the preparation of 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethox y)-1-methyl-1H-benzimidazole-6-carboxamide represented by the following structural formula-1, which ...
WO/2023/128786A1	NEW ANTIVIRAL TRIAZOLE DERIVATIVES, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN VIRAL INFECTIONS A family of triazole derivatives is described. Also described is the use of these triazole derivatives in treating or preventing viral infections, such as human immunodeficiency virus (HIV) infections, and the diseases caused by these in...

Matches 351 - 400 out of 30,869	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >